Literature DB >> 18500599

[Austrian expert opinion on the standard for expert assessment of course of illness in patients with chronic polyarthritis (rheumatoid arthritis)].

Klaus P Machold1, Hans Peter Brezinsek, Burkhard F Leeb, Stephan Pflugbeil, Franz Rainer, Franz Singer, Martin Skoumal, Tanja A Stamm, Manfred Herold.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18500599     DOI： 10.1007/s00508-008-0958-9

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   1.704


× No keyword cloud information.
  80 in total

Review 1.  Scoring radiographic abnormalities in rheumatoid arthritis.

Authors:  J T Sharp
Journal:  Radiol Clin North Am       Date:  1996-03       Impact factor: 2.303

2.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

3.  The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis.

Authors:  E J Kroot; B A de Jong; M A van Leeuwen; H Swinkels; F H van den Hoogen; M van't Hof; L B van de Putte; M H van Rijswijk; W J van Venrooij; P L van Riel
Journal:  Arthritis Rheum       Date:  2000-08

Review 4.  Autoantibodies to the A/B proteins of the heterogeneous nuclear ribonucleoprotein complex: novel tools for the diagnosis of rheumatic diseases.

Authors:  G Steiner; K Skriner; J S Smolen
Journal:  Int Arch Allergy Immunol       Date:  1996-12       Impact factor: 2.749

5.  Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis.

Authors:  Floris A van Gaalen; Jill van Aken; Tom W J Huizinga; Geziena M Th Schreuder; Ferdinand C Breedveld; Eric Zanelli; Walther J van Venrooij; Cornelis L Verweij; René E M Toes; René R P de Vries
Journal:  Arthritis Rheum       Date:  2004-07

6.  Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression.

Authors:  P T Dawes; P D Fowler; S Clarke; J Fisher; A Lawton; M F Shadforth
Journal:  Br J Rheumatol       Date:  1986-02

7.  Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

Authors:  J S Smolen; J R Kalden; D L Scott; B Rozman; T K Kvien; A Larsen; I Loew-Friedrich; C Oed; R Rosenburg
Journal:  Lancet       Date:  1999-01-23       Impact factor: 79.321

8.  The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease.

Authors:  M A van Leeuwen; M H van Rijswijk; D M van der Heijde; G J Te Meerman; P L van Riel; P M Houtman; L B van De Putte; P C Limburg
Journal:  Br J Rheumatol       Date:  1993-06

9.  Lack of agreement between patients' and physicians' perspectives of rheumatoid arthritis disease activity changes.

Authors:  B F Leeb; J Sautner; B A Leeb; C Fassl; B Rintelen
Journal:  Scand J Rheumatol       Date:  2006 Nov-Dec       Impact factor: 3.641

10.  Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.

Authors:  Daniel Aletaha; Valerie P K Nell; Tanja Stamm; Martin Uffmann; Stephan Pflugbeil; Klaus Machold; Josef S Smolen
Journal:  Arthritis Res Ther       Date:  2005-04-07       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.